Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT
NEW INDICATION OF XUANZHU BIOPHARM'S BIREOCICLIB INCLUDED IN THE 2026 NRDL

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**" or "**Sihuan Pharmaceutical**", together with its subsidiaries, the "**Group**") is pleased to announce that the new indication of Bireociclib Tablets, an innovative drug independently developed by the Group's non wholly-owned subsidiary Xuanzhu Biopharmaceutical Co., Ltd. ("**Xuanzhu Biopharm**", stock code: 02575.HK), in combination with aromatase inhibitors ("**AIs**") for the first-line treatment of patients with hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) ("**HR+/HER2-**") advanced breast cancer, has been included in the National Drug List for Basic Medical Insurance, Maternity Insurance and Work-Related Injury Insurance (2026) (the "**2026 NRDL**"). The 2026 NRDL will officially take effect on 1 January 2027. As of the date of this announcement, all three indications of Bireociclib approved in Mainland China have been included in the NRDL.

With the inclusion of the new indication of Bireociclib Tablets in combination with AIs for the first-line treatment of HR+/HER2- advanced breast cancer in the 2026 NRDL, Bireociclib will achieve full medical insurance reimbursement coverage across the first-line, second-line and later-line treatment scenarios of HR+/HER2- advanced breast cancer. This is expected to help reduce the financial burden of medication on relevant patients and enhance the accessibility of this innovative drug.

The Board believes that the inclusion will further expand the potential patient population benefiting from Bireociclib and help accelerate its hospital access and clinical application, thereby promoting the commercialisation of Bireociclib and further consolidating Xuanzhu Biopharm and the Group's competitive advantages in the field of HR+/HER2- advanced breast cancer treatment.

ABOUT BIREOCICLIB

Bireociclib Tablets (trade name: Xuan Yue Ning), as the first CDK2/4/6 inhibitor approved in China, possess a unique multi-target synergistic mechanism of action, offering advantages including potent inhibition of tumor cell proliferation and significant reduction of the hematological toxicity commonly associated with traditional CDK4/6 inhibitors. Currently, Bireociclib Tablets have been approved by the National Medical Products Administration (NMPA) for three indications, namely: (i) in combination with AIs for the initial endocrine treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer; (ii) in combination with fulvestrant for the treatment of adult patients with HR+/HER2- locally advanced or metastatic breast cancer who have experienced disease progression following prior endocrine therapy; and (iii) as monotherapy for the treatment of adult patients with HR+/HER2- advanced or metastatic breast cancer who have experienced disease progression following two or more prior endocrine therapies and one chemotherapy regimen during the metastatic stage. As of the date of this announcement, all three indications have been included in the NRDL.

ABOUT XUANZHU BIOPHARM

Xuanzhu Biopharm was listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2025 (stock code: 02575.HK). It is an innovative pharmaceutical enterprise rooted in China with a global-minded vision. Focusing on major disease areas including gastroenterology, oncology and metabolism, the company is committed to the research and development ("**R&D**"), production and commercialisation of Class 1 new drugs with core independent intellectual property rights. As an R&D-driven commercial-stage biotech innovator empowered by AI, the company has built a synergistic technical system integrating small-molecule drug R&D platforms, biologic drug R&D platforms and AI-driven drug discovery platforms. This enables it to maintain one of the rare domestic product pipelines covering multiple modalities such as small-molecule chemicals, large-molecule biologics and antibody-drug conjugates (ADCs). Guided by unmet clinical needs, the company strives to evolve into a first-class innovative pharmaceutical enterprise with in-house capabilities for research-and-development, manufacturing and sales.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetics and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 16 November 2026

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong and Ms. Chen Yanling; the non-executive director of the Company is Mr. Che Yuxuan; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.